BRIEF-Immunovaccine posts positive early stage trial results of DPX-survivac in ovarian cancer

Thu Aug 25, 2016 7:15am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 25 (Reuters) - Immunovaccine Inc:

* Immunovaccine announces additional positive top-line results from phase 1/1b clinical trial program with DPX-survivac in ovarian cancer

* Trial had no unexpected treatment-related serious adverse events Source text for Eikon: Further company coverage: